EUVIMEDEUVIMED entdecken
Crossref

Reactivation of stable neovascular age‐related macular degeneration following treat‐and‐extend regimen discontinuation

Jose Carlo M Artiaga iD, Shiao Wei Wong iD, Deepthy Menon, Swetha Kumar, Pankaja Dhoble iD, Sridevi Thottarath, Luke Nicholson iD

Clinical & Experimental Ophthalmology · 2025-01 · 53 (1) · 76-83

DOI: 10.1111/ceo.14444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 02.10.2024. Verfasst von Jose Carlo M Artiaga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Retina Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Wet Macular Degeneration, Visual Acuity, Recombinant Fusion Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To describe the incidence and pattern of reactivation of neovascular age‐related macular degeneration (nAMD) following successful treatment with treat‐and‐extend intravitreal anti‐vascular endothelial growth factor therapy.

Methods

Consecutive patients with treated nAMD who did not require further treatment over a 6‐month period and who attended their 3‐monthly optical coherence tomography monitoring clinic in Moorfields Eye Hospital from 1 November 2019 to 31 January 2020 were included. Patients with diagnoses of macular neovascularization other than AMD, and patients with incomplete data were excluded. Baseline demographics recorded were age, sex, race, laterality, cause of macular neovascularization, drug, number of injections, and duration of treatment. Date, setting, symptoms, and time to retreatment were collected among patients with disease reactivation.

Results

The medical records of 286 patients were included. Most patients were female (64.3%), white (68.18%), and were receiving aflibercept monotherapy (55.2%). Mean number of injections at baseline was 17.79 ± 11.74 (range 3–62) with a mean treatment duration of 39.47 ± 30.68 months (range 2–139). Reactivation of AMD was identified in 32.2% of cases with 87% of recurrences identified via scheduled visit. The most common symptom was blurring of vision in 44.6%, while 39.1% were asymptomatic. Mean time from baseline to retreatment was 29.37 ± 22.40 months (range 5–104), with 20.7%, 73.9% and 88.04% of these patients requiring retreatment within 1, 3, and 5 years, respectively.

Conclusions

Despite prior treatment with no reactivation in 6 months, 32.2% reactivate, 73.9% of which within 3 years. A significant proportion, 39.1%, reactivated without symptoms necessitating regular monitoring in the first 5 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsWet Macular DegenerationVisual AcuityRecombinant Fusion ProteinsRanibizumabHumansFemaleMaleIntravitreal InjectionsAgedTomography, Optical CoherenceVascular Endothelial Growth Factor AReceptors, Vascular Endothelial Growth FactorAged, 80 and overRetrospective StudiesFluorescein AngiographyMiddle AgedFollow-Up StudiesRecurrenceWithholding TreatmentIncidence

Stichwörter der Autor:innen

age‐related macular degenerationintravitreal injectionremote monitoringretinavirtual clinic

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor AReceptors, Vascular Endothelial Growth FactorafliberceptRecombinant Fusion ProteinsRanibizumabVEGFA protein, human

Autor:innen und Institutionen

  • Medical Retina Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
  • Department of Ophthalmology and Visual Sciences, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.
  • Manchester Royal Eye Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.

ORCID-Profile: Jose Carlo M Artiaga, Shiao Wei Wong, Pankaja Dhoble, Luke Nicholson

Zitieren

APA

Artiaga, J. C. M., Wong, S. W., Menon, D., Kumar, S., Dhoble, P., Thottarath, S., & Nicholson, L. (2025). Reactivation of stable neovascular age‐related macular degeneration following treat‐and‐extend regimen discontinuation. Clinical & Experimental Ophthalmology, 53(1), 76-83. https://doi.org/10.1111/ceo.14444

Vancouver

Artiaga JCM, Wong SW, Menon D, Kumar S, Dhoble P, Thottarath S, et al. Reactivation of stable neovascular age‐related macular degeneration following treat‐and‐extend regimen discontinuation. Clinical & Experimental Ophthalmology. 2025;53(1):76-83. doi:10.1111/ceo.14444

BibTeX
@article{Artiaga2025,
  author = {Artiaga, Jose Carlo M and Wong, Shiao Wei and Menon, Deepthy and Kumar, Swetha and Dhoble, Pankaja and Thottarath, Sridevi and Nicholson, Luke},
  title = {Reactivation of stable neovascular age‐related macular degeneration following treat‐and‐extend regimen discontinuation},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2025},
  volume = {53},
  number = {1},
  pages = {76--83},
  doi = {10.1111/ceo.14444}
}
Kostenlos starten →